Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carbazoles / administration & dosage
  • Carbazoles / adverse effects
  • Carbazoles / therapeutic use*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors*
  • Janus Kinase Inhibitors / administration & dosage
  • Janus Kinase Inhibitors / adverse effects
  • Janus Kinase Inhibitors / therapeutic use*
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / metabolism
  • Treatment Outcome

Substances

  • Carbazoles
  • Janus Kinase Inhibitors
  • lestaurtinib
  • JAK2 protein, human
  • Janus Kinase 2